HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Atrial natriuretic peptide protects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice : ANP for pulmonary fibrosis.

AbstractBACKGROUND:
Pulmonary fibrosis is a life-threatening disease characterized by progressive dyspnea and worsening pulmonary function. Atrial natriuretic peptide (ANP), a heart-derived secretory peptide used clinically in Japan for the treatment of acute heart failure, exerts a wide range of protective effects on various organs, including the heart, blood vessels, kidneys, and lungs. Its therapeutic properties are characterized by anti-inflammatory and anti-fibrotic activities mediated by the guanylyl cyclase-A (GC-A) receptor. We hypothesized that ANP would have anti-fibrotic and anti-inflammatory effects on bleomycin (BLM)-induced pulmonary fibrosis in mice.
METHODS:
Mice were divided into three groups: normal control, BLM with vehicle, and BLM with ANP. ANP (0.5 μg/kg/min via osmotic-pump, subcutaneously) or vehicle administration was started before BLM administration (1 mg/kg) and continued until the mice were sacrificed. At 7 or 21 days after BLM administration, fibrotic changes and infiltration of inflammatory cells in the lungs were assessed based on histological findings and analysis of bronchoalveolar lavage fluid. In addition, fibrosis and inflammation induced by BLM were evaluated in vascular endothelium-specific GC-A overexpressed mice. Finally, attenuation of transforming growth factor-β (TGF-β) signaling by ANP was studied using immortalized mouse endothelial cells stably expressing GC-A receptor.
RESULTS:
ANP significantly decreased lung fibrotic area and infiltration of inflammatory cells in lungs after BLM administration. Furthermore, similar effects of ANP were observed in vascular endothelium-specific GC-A overexpressed mice. In cultured mouse endothelial cells, ANP reduced phosphorylation of Smad2 after TGF-β stimulation.
CONCLUSIONS:
ANP exerts protective effects on BLM-induced pulmonary fibrosis via vascular endothelial cells.
AuthorsAtsuko Okamoto, Takashi Nojiri, Kazuhisa Konishi, Takeshi Tokudome, Koichi Miura, Hiroshi Hosoda, Jun Hino, Mikiya Miyazato, Yohkoh Kyomoto, Kazuhisa Asai, Kazuto Hirata, Kenji Kangawa
JournalRespiratory research (Respir Res) Vol. 18 Issue 1 Pg. 1 (01 03 2017) ISSN: 1465-993X [Electronic] England
PMID28049526 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Immunologic Factors
  • Bleomycin
  • Atrial Natriuretic Factor
Topics
  • Animals
  • Atrial Natriuretic Factor (administration & dosage)
  • Bleomycin
  • Endothelial Cells (drug effects, immunology, pathology)
  • Immunologic Factors (immunology)
  • Lung (drug effects, immunology, pathology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Pulmonary Fibrosis (drug therapy, immunology, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: